July 19, 2022
Incyte’s Opzelura™ (ruxolitinib) cream has been approved for the topical treatment of nonsegmental vitiligo in patients who are at least 12 years old. Vitiligo is an autoimmune condition that destroys melanocytes, leading to depigmentation of the skin.
- This is the second indication for the drug, which has been FDA approved since 2011 for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in certain patients at least 12 years of age.
- Recommended dosing for vitiligo is a thin layer of cream applied twice daily to affected areas of up to 10% of the body’s surface area.